This trial explanation is interesting. The study
Post# of 36537
(Total Views: 311)
Posted On: 07/18/2019 2:16:38 PM
This trial explanation is interesting. The study is complex, with two arms, first a safety arm followed by an efficacy arm. Only those patients with active metastatic TNC are included it looks like.
There is a near term secondary outcome measure - Overall survival rate at 1 year from start of therapy.
I wonder if the first patient has been dosed.
There is a near term secondary outcome measure - Overall survival rate at 1 year from start of therapy.
I wonder if the first patient has been dosed.
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼